Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Stock Information for OptiNose Inc.
Loading
Please wait while we load your information from QuoteMedia.